Last week marked the end of the greatest amount of biotech activity across a two-week stretch in over a decade (14 pricings from 1/29 to 2/11). However, without any superstar performers like January’s Dicerna (DRNA; up 160%) or Ultragenyx (RARE; 110%),...read more
The week’s five health sector IPOs have produced lackluster returns; together they are down 1% on average from their IPO prices. Amedica (AMDA), which creates improved spine, hip and joint replacements, dropped 6% today after pricing at the largest...read more
NephroGenex, a clinical-stage biotech developing treatments for diabetic nephropathy, raised $37 million by offering 3.1 million shares at $12, the low end of the range of $12 to $14. NephroGenex plans to list on the NASDAQ under the symbol NRX. NephroGenex...read more
US IPO Recap: Wave goodbye to the biotech wave as tech prepares to take over
Last week marked the end of the greatest amount of biotech activity across a two-week stretch in over a decade (14 pricings from 1/29 to 2/11). However, without any superstar performers like January’s Dicerna (DRNA; up 160%) or Ultragenyx (RARE; 110%),...read more
Health IPOs down 1% and housing IPOs trade up after heavy discount
The week’s five health sector IPOs have produced lackluster returns; together they are down 1% on average from their IPO prices. Amedica (AMDA), which creates improved spine, hip and joint replacements, dropped 6% today after pricing at the largest...read more
NephroGenex prices IPO at $12, the low end of the range
NephroGenex, a clinical-stage biotech developing treatments for diabetic nephropathy, raised $37 million by offering 3.1 million shares at $12, the low end of the range of $12 to $14. NephroGenex plans to list on the NASDAQ under the symbol NRX. NephroGenex...read more
9 US IPOs planned for the week of Feb 10
The following IPOs are expected to price this week: Amedica (AMDA), which develops and sells medical devices using its silicon nitride technology platform, plans to...read more